Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders

Article ID	Journal	Published Year	Pages	File Type
8479417	Neurochemistry International	2008	32 Pages	PDF

Abstract

The association between lipoprotein receptor LRP11 variants and sporadic Alzheimer's disease (SAD) offers scope to integrate components of pre- and post-Golgi membranes, or brain clathrin-coated vesicles within pathways for trafficking as targets for intervention. The presence of APP and metabolites in brain clathrin-coated vesicles as significant cargo with lipoproteins and adaptors focuses attention as targets for therapeutic intervention. This overview emphasizes the importance to develop new therapies targeting neurosecretases to treat a major neurological disorder that has vast economic and social implications.

Keywords

SORLA SNAPs VPS VAMP vesicle associated membrane protein NSAIDS TACE NCT SNAREs NICD APH VHS Presenilin enhancer 2 Tissue inhibitors of metalloproteases PEN-2 ADDL APLP BACE AICD APP CAA GGA Nicastrin ADAM insulin degrading enzyme cerebral amyloid angiopathy IDE FAD Alzheimer's disease Sporadic Alzheimer's disease familial Alzheimer's disease a disintegrin and metalloprotease Transgenic tumor necrosis factor α Non-steroidal anti-inflammatory drugs APP intracellular domain intracellular domain Notch intracellular domain transmembrane domain ICD TIMP Down's syndrome endoplasmic reticulum Senile plaque SAD TNF-α Vacuolar protein sorting knock-out RIP Presenilin regulated intramembrane proteolysis amyloid precursor protein Signal peptide